4-乙酰基-1,3-二氟苯硝化反应机理研究

以4-氨基-1,3-二氟苯、乙酸酐和浓硝酸等为原料,合成了4-乙酰基-5-硝基-1,3-二氟苯,并且采用FTIR和1H NMR对产物进行了表征.采用量子化学方法,探讨了在酸催化条件下4-乙酰基-1,3-二氟苯硝化反应过程中的微观机理,在密度泛函理论的B3LYP/6-311G**水平下搜索得到反应路径,并对各中间体、过渡态和产物进行几何优化、振动频率分析和标准热力学函数计算;反应路径经过IRC验证.在MP2/6-311G**水平上对所有中间体、过渡态和产物进行更精确的能量计算.     

HIV-1 RT抑制剂研究I.1,3-二苄基-6-(3,4-环氧丁基)尿嘧啶的合成

报道了1,3-二苄基-6-(3,4-环氧丁基)尿嘧啶的合成新方法.以6-甲基尿嘧啶(1)为起始物,经1,3-二苄基-6-甲基尿嘧啶(2)及未见文献报道的1,3-二苄基-6-(3-丁烯基)尿嘧啶(3)和1,3-二苄基-6-(3-羟基-4-溴丁基)尿嘧啶(4),首次高收率合成了1,3-二苄基-6-(3,4-环氧丁基)尿嘧啶(5),并对其化学结构进行了表征.     

2-(1,2-亚乙/1,3-亚丙二硫)亚甲基-3-羰基丁酰氯的制备及其与芳烃的酰化反应

制备了较稳定的2-(1,2-亚乙/1,3-亚丙二硫)亚甲基-3-羰基丁酰氯,并实现了其与芳烃的酰化反应,为1-芳基-2-(1,2-亚乙/1,3-亚丙二硫)亚甲基-1,3-丁二酮的合成提供了一条新途径.     

1,3-噻唑烷衍生物的合成、结构及生物活性

为了寻找新的含噻唑杂环的先导化合物, 利用2-取代-1,3-噻唑烷1与氯甲酸取代苯基酯2及取代苯基甲酰氯4在三乙胺存在下发生缩合反应, 合成了6个2-取代-1,3-噻唑烷-3-甲酸酯类化合物3和5个N-苯甲酰基-2-取代-1,3-噻唑烷类化合物5, 并利用¹H NMR, IR, MS, 元素分析对其结构进行了表征. 用X-ray单晶衍射测定了2-硫代-1,3-噻唑烷-3-甲酸苯酯(3d)和N-苯甲酰基-2-氧代-1,3-噻唑烷(5a)的晶体结构, 证实了氯甲酸酯与2-硫代-1,3-噻唑烷的反应产物为硫酮式结构, 而非硫酯式结构. 初步生物活性试验结果表明, 在试验浓度下部分目标化合物3和5具有一定的杀菌和杀虫活性.     

1,3-二芳基-1丙酮类化合物的合成

以取代苯乙酮和取代芳香醛为原料,制得一系列1,3-二芳基-1-氧代丙烯类化合物(1a~1j); 1a~1j和对甲苯磺酰肼(2)经还原反应合成了10个1,3-二苯基-1-丙酮类化合物(3a~3j, 3h为新化合物),其结构经¹H NMR, ¹³C NMR, IR和HR-MS（ESI）确证。研究了碱、溶剂、温度和投料比γ[n(1a)/n(2)/n(碱)]对3a产率的影响。结果表明：γ=1/2/2,磷酸钾为碱,乙醇为溶剂,于80 ℃反应4 h, 3a产率最高（80%）。     

二茂铁偶姻衍生物前体——2-二茂铁基-2-(芳基羟甲基)-1,3-二噻烷的合成

用2-二茂铁基-1,3-二噻烷的锂代物与芳基羰基化合物的反应,合成了16种2-二茂铁基-2-(芳基羟甲基)-1,3-二噻烷.简要讨论了产物的¹HNMR谱以及羰基化合物结构对反应的影响.     

5-溴-1,3-二氟-2-甲氧基苯的合成

以5-溴-1,2,3-三氟苯为原料,经氰化取代,甲氧基化,氰基酸性水解,霍夫曼降级重排,重氮化和Gattermann反应,高效合成了5-溴-1,3-二氟-2-甲氧基苯,其结构经¹H NMR, 13C NMR和MS(EI)确证。并利用气相色谱（GC）和高效液相色谱（HPLC）实时监测反应进程,优化了合成条件。     

2-烷基-1,3-丙二醇β-溴丙醛缩醛的合成及表征

2-烷基-1,3-丙二醇β-溴丙醛缩醛又名5-烷基-2-溴乙基-1,3-二氧六环(3),是合成含1,3-二氧六环的可断裂表面活性剂的中间体[1],这种表面活性剂在中性和碱性条件下很稳定,在酸性条件下易断环变成非表面活性剂,这样可克服在有机合成、分析化学以及研究胶束中的反应等使用普通表面活性剂时因存在令人讨厌的乳浊液而使产物难以分离的缺陷.因此,研究和开发这类表面活性剂,无论在理论上,还是在应用中都具有十分重要的意义.     

Pt/WO3/ZrO2 催化甘油选择性脱羟基制 1,3-丙二醇反应的溶剂效应

 考察了不同溶剂中 Pt/WO3/ZrO2 催化剂催化甘油加氢制 1,3-丙二醇的反应性能. 结果表明, 质子溶剂乙醇和水有利于甘油转化为 1,3-丙二醇. 含有乙醇或水的二元混合溶剂表现出明显的溶剂组分协同效应, 使用混合溶剂时 1,3-丙二醇选择性超过使用单一溶剂, 而且混合溶剂的组成对反应性能影响很大.     

5-氨基-1,3-二氢-1,3-二氧-异吲哚-2-丙酸类衍生物的合成及抗血管生成活性研究

根据RGD序列肽的构效关系, 设计并合成了一系列以5-氨基-1,3-二氢-1,3-二氧-异吲哚-2-丙酸为分子骨架的新化合物. 其中间体和目标物的化学结构经¹H NMR, MS和元素分析确证. 体外初步生物活性筛选结果表明, 目标物在10^－5 mol/L浓度下对bFGF诱导的鸡胚绒毛尿囊膜新生血管生成有显著抑制活性.     

Synthesis and antiangiogenic activities of 5-amino-1,3-dihydro-1, 3-dioxo-2H-isoindole-2-propanoic acid derivatives

Based on the structure-activity relationships and antiangiogenic mechanism of RGD-containing peptides,a series of 5-amino- 1,3-dihydro-1,3-dioxo-2H-isoindole derivatives were synthesized.The structures were characterized by ~1H NMR,MS and elementary analysis.There ability to inhibit angiogenesis were evaluated by chick embryo chorioallantoic membrane assay at 10~(-5) mol/L.Compounds 7a and 7b displayed obvious antiangiogenic activity.     

Synthesis of Some Potential Antiangiogenic 1,3-Dihydro-1,3-dioxo-2H-isoindole Derivatives

The proliferation, invasion and metastasis of malignant tumors are closely related withangiogenesis induced by tumor cells. Blocking tumor-induced angiogenesis is anefficient strategy to prevent and cure cancer1. Recent studies indicated that theangiogenic process depends on vascular endothelial cell migration and invasion, whichregulated by αvβ3 receptor2. The receptor and extracellular matrix can recognize eachother through Arg-Gly-Asp (RGD) consensus sequence found in matrix ligands…     

Radio‐Analytical Determination of the Coating Efficiency of Cyclic RGD Peptides

Coating of artificial surfaces with RGD (= arginine‐glycine‐aspartate) peptides to enhance cell adhesion is an ongoing issue. Thereby, the physiological adhesion process to the extra‐cellular matrix (ECM) is mimicked by the peptide coating, leading to a strong cell‐surface contact, followed by spreading and proliferation of the cells. For comparable cell adhesion studies, it is important to know the density of the RGD peptides on the surface. Here, we present an approach to determine the amount of bound cyclic RGD peptide by radio labeling with ¹²⁵I of a tyrosine‐containing RGD peptide on different materials surfaces (poly(methyl methacrylate) (PMMA), titanium, and silicon). For all surfaces, the amount of bound peptides is in the range of pmol/cm¹.     

Adhesion behaviors of human trophoblast cells by contact with endothelial cells

Although it is still not clear whether migratory trophoblasts reach the spiral arteries by migration within blood vessels against blood flow or by a mechanism of directional cell division/proliferation, this process involves the attachment and adhesion of trophoblasts to endothelial cells lining the blood vessel walls. This raises the possibility that the cell–cell contact with endothelial cells may regulate trophoblast cell adhesion behaviors according to the surrounding flow condition. To test this, the adhesion forces of early gestation human trophoblast cells (TCs) cultured on glass slides coated with type I rat collagen or cultured with human umbilical vein endothelial cells (HUVECs) were measured quantitatively using a micropipette aspiration technique. Then, the resistance of TCs co-cultured with HUVECs to flow-induced shear stress was assessed with a flow chamber technique. The results showed that the adhesion force of TCs to glass slides coated with collagen was positively correlated with the concentration of collagen. By contact with endothelial cells, the adhesion force and the resistance to shear stress for the TCs were significantly enhanced. The interdiction of integrin β1 interaction remarkably reduced the adhesion forces of TCs to endothelial cells, hence their resistance to shear stress. The results therefore suggest that the contacts of TCs with endothelial cells enhance the adhesion forces of human TCs, partially by regulating with the integrin β1 according to the flow condition (i.e., the shear stress) in such a way to prevent the TCs from being carried downstream by flowing blood.     

An αv‐RGD Integrin Inhibitor Toolbox: Drug Discovery Insight,Challenges and Opportunities

There is a requirement for efficacious and safe medicines to treat diseases with high unmet need. The resurgence in αv‐RGD integrin inhibitor drug discovery is poised to contribute to this requirement. However, drug discovery in the αv integrin space is notoriously difficult due to the receptors being structurally very similar as well as the polar zwitterionic nature of the pharmacophore. This Review aims to guide drug discovery research in this field through an αv inhibitor toolbox, consisting of small molecules and antibodies. Small‐molecule αv tool compounds with extended profiles in αvβ1, 3, 5, 6 and 8 cell adhesion assays, with key physicochemical properties, have been collated to assist in the selection of the right tool for the right experiment. This should also facilitate an understanding of partial selectivity profiles of compounds generated in different assays across research institutions. Prospects for further αv integrin research and the critical importance of target validation are discussed, where increased knowledge of the selectivity for individual RGD αv integrins is key. Insights into the design of small‐molecule RGD chemotypes for topical or oral administration are provided and clinical findings on advanced molecules are examined.     

Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin alpha(V)beta(3).

The process of new blood vessel growth from existing vasculature, known as angiogenesis, is critical to several pathological conditions, most notably cancer. Both MMP2, which degrades the extracellular matrix (ECM), and integrin alpha(V)beta(3), which contributes to endothelial cell attachment to the ECM, are critically involved in this process. Recent findings have shown that MMP2 is localized in an active form on the surface of invasive endothelial cells based on its ability to directly bind integrin alpha(V)beta(3), suggesting that disrupting this protein--protein interaction may represent a new target for the development of angiogenesis inhibitors. The screening of small molecule libraries led to the identification of compounds which disrupt the MMP2--alpha(V)beta(3) interaction in an in vitro binding assay. A prototypical inhibitor was further found to prevent the degradation of the protein matrix without directly inhibiting MMP2 activity or disrupting the binding of alpha(V)beta(3) to its classical ECM ligand, vitronectin. The synthesis and screening of analogues and substructures of this lead compound allowed the identification of requisite structural features for inhibition of MMP2 binding to alpha(V)beta(3). This led to the synthesis of a more water-soluble derivative which maintains the in vitro biological properties and has potent antiangiogenic and antitumor activity in vivo, validating the target as one useful for therapeutic intervention.     

α-蒎烯和间戊二烯共聚工艺

研究了共聚反应条件对α-蒎烯（α-P）和间戊二烯(PD)共聚产物的影响,确定最佳反应条件为：反应时间2 h,原料比例n(α-P)∶n(PD)=1∶2,反应温度15 ℃,溶剂甲苯,催化剂AlCl3用量为单体总质量1%,获得产物树脂的收率为72.3%,软化点为121.3 ℃,色度为4,相对分子质量为1549,相对分子质量分布为1.92。 其热稳定性和粘结相容性好。     

Cyclic aza-peptide integrin ligand synthesis and biological activity

Aza-peptides are obtained by replacement of the α-C-atom of one or more amino acids by a nitrogen atom in a peptide sequence. Introduction of aza-residues into peptide sequences may result in unique structural and pharmacological properties, such that aza-scanning may be used to probe structure-activity relationships. In this study, a general approach for the synthesis of cyclic aza-peptides was developed by modification of strategies for linear aza-peptide synthesis and applied in the preparation of cyclic aza-pentapeptides containing the RGD (Arg-Gly-Asp) sequence. Aza-amino acid scanning was performed on the cyclic RGD-peptide Cilengitide, cyclo[R-G-D-f-N(Me)V] 1, and its parent peptide cyclo(R-G-D-f-V) 2, potent antagonists of the αvβ3, αvβ5, and α5β1 integrin receptors, which play important roles in human tumor metastasis and tumor-induced angiogenesis. Although incorporation of the aza-residues resulted generally in a loss of binding affinity, cyclic aza-peptides containing aza-glycine retained nanomolar activity toward the αvβ3 receptor.